Skip to main content

Table 3 Multivariate analysis for all clinical outcomes stratified for NCCN risk group and the best-identified cut-point for MIBC (60%)

From: The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer

Covariate FFBF FFM CSS OS
  HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
NCCN risk group         
 Low Reference   Reference   Reference   Reference  
 Intermediate 1.7 (0.83-3.4) 0.15 2.8 (0.80-9.8) 0.11 2.1 (0.23-19.7) 0.51 1.2 (0.57-2.5) 0.65
 High 3.2 (1.6-6.5) 0.001 4.6 (1.3-16.2) 0.02 6.9 (0.8-59.6) 0.08 3.0 (1.5-6.1) 0.002
MIBC         
 <60% Reference   Reference   Reference   Reference  
 ≥60% 1.9 (1.2-2.9) 0.008 1.6 (0.81-3.1) 0.19 2.2 (0.72-6.9) 0.16 1.0 (0.59-1.7) 0.99
  1. Abbreviations: MIBC = maximum involvement of biopsy core; FFBF = freedom from biochemical failure; FFM = freedom from metastasis; CSS = cause specific survival; OS = overall survival; HR = hazard ratio; CI = confidence interval.